187 related articles for article (PubMed ID: 18816410)
1. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.
Peng XC; Yang L; Yang LP; Mao YQ; Yang HS; Liu JY; Zhang DM; Chen LJ; Wei YQ
J Exp Clin Cancer Res; 2008 Sep; 27(1):46. PubMed ID: 18816410
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.
Li HX; Zhao XY; Wang L; Wang YS; Kan B; Xu JR; Li J; Wen YJ; Peng XC; Chen X; Yan F; Ye B; Du XB; Zhao JM; Yi T; Chen XC; Du XX; Wei YQ; Zhao X
Med Oncol; 2010 Dec; 27(4):1156-63. PubMed ID: 19949901
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.
Pan L; Peng XC; Leng F; Yuan QZ; Shan Y; Yu DD; Li ZY; Chen X; Xiao WJ; Wen Y; Ma TT; Yang L; Mao YQ; Yang HS; Wei YQ; Wang CT
J Cancer Res Clin Oncol; 2011 Jan; 137(1):19-28. PubMed ID: 20217127
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration.
Shan Y; Wang C; Yang L; Chen LJ; Deng HX; Yang HS; Li Z; Li Z; Pan L; Leng F; Wei Y
J Biosci; 2010 Jun; 35(2):209-16. PubMed ID: 20689177
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor radiosensitivity by a survivin dominant-negative mutant.
Yuan QZ; Wang CT; Mao YQ; Zhang P; Shi HS; Li ZY; Pan L; Yu DD; Leng F; Chen X; Ying W; Xu JH; Li W; Wu F; Wen Y; Ma TT; Wei YQ
Oncol Rep; 2010 Jan; 23(1):97-103. PubMed ID: 19956869
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.
Yu DD; Wang CT; Shi HS; Li ZY; Pan L; Yuan QZ; Leng F; Wen Y; Chen X; Wei YQ
J Exp Clin Cancer Res; 2010 May; 29(1):46. PubMed ID: 20462440
[TBL] [Abstract][Full Text] [Related]
8. [Anti-prostate cancer activity of Survivin-T34A mutant in vitro and in vivo].
Pan L; Peng XC; Yuan QZ; Leng F; Yu DD; Shan Y; Li ZY; Wang CT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May; 41(3):390-3. PubMed ID: 20629305
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lymphatic metastases by a survivin dominant-negative mutant.
Xu GC; Zhang P; Leng F; Pan L; Li ZY; Yu DD; Shan Y; Yuan QZ; Wen Y; Mu B; Shi HS; Chen X; Wang CT
Oncol Res; 2012; 20(12):579-87. PubMed ID: 24139416
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor and antimetastatic activities of plasmid pcDNA3. 1-IP10 complexed with cationic liposome in mice with 4T1 breast cancer].
Tang QQ; Shi W; Lü HM; Peng XC; Wen YJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):195-8. PubMed ID: 19462888
[TBL] [Abstract][Full Text] [Related]
11. [Anti-tumor effects of recombinant adenovirus encoding survivin encapsulated in cationic liposome].
Yang YL; Ding ZY; Li Q; Zhou H; Deng HX; Tian L; Wei YQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):704-7. PubMed ID: 17037732
[TBL] [Abstract][Full Text] [Related]
12. Combination of DESI2 and endostatin gene therapy significantly improves antitumor efficacy by accumulating DNA lesions, inducing apoptosis and inhibiting angiogenesis.
Yan H; Guo W; Li K; Tang M; Zhao X; Lei Y; Nie CL; Yuan Z
Exp Cell Res; 2018 Oct; 371(1):50-62. PubMed ID: 30055135
[TBL] [Abstract][Full Text] [Related]
13. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
[TBL] [Abstract][Full Text] [Related]
14. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
15. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
[TBL] [Abstract][Full Text] [Related]
16. [Effects of Survivin-T34A mutant on breast cancer cell in vitro and in vivo].
Deng X; Song H; Ren M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Jun; 31(3):648-51. PubMed ID: 25219251
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Characterization of a New Cationic Lipid: Efficient siRNA Delivery and Anticancer Activity of Survivin-siRNA Lipoplexes for the Treatment of Lung and Breast Cancers.
Vaidya S; Mohod A; Eedara AC; Andugulapati SB; Pabbaraja S
ChemMedChem; 2023 Aug; 18(16):e202300097. PubMed ID: 37306531
[TBL] [Abstract][Full Text] [Related]
18. Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells.
Kim CK; Haider KH; Choi SH; Choi EJ; Ahn WS; Kim YB
Gynecol Oncol; 2002 Jan; 84(1):85-93. PubMed ID: 11748982
[TBL] [Abstract][Full Text] [Related]
19. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
[TBL] [Abstract][Full Text] [Related]
20. Liposome-mediated DNA immunisation via the subcutaneous route.
Perrie Y; McNeil S; Vangala A
J Drug Target; 2003; 11(8-10):555-63. PubMed ID: 15203925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
